High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

This is a randomized, open-label, Phase I clinical study with expansion. It will assess the safety and efficacy of high-dose ascorbate administered concomitantly with azacitidine and venetoclax in newly diagnosed AML.

Trial Details

NCT ID
NCT07177079
Phase
PHASE1
Sponsor
Kittika Poonsombudlert
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Azacitidine
  • Venetoclax
  • High-dose ascorbate
  • Decitabine
Locations (sample)
  • Iowa City, Iowa, United States|41.66113,-91.53017

Key Eligibility Criteria

  • Adults aged ≥ 18 who are deemed unfit for intensive chemotherapy by meeting at least one of the following criteria:
  • Eastern Cooperative Oncology Group (ECOG) performance of 2-3
  • Severe cardiac disorder (e.g., congestive heart failure requiring treatment, ejection fraction ≤ 50%, or chronic stable angina)
  • Severe pulmonary disorder (e.g., DLCO ≤ 65% or FEV1 ≤ 65%)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →